首页> 美国卫生研究院文献>Journal of Cancer >Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
【2h】

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

机译:完成多发性骨髓瘤的硼替佐米-沙利度胺-地塞米松(VTd)诱导方案完成时的部分反应并不排除合并中对VTd的反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The impact of consolidation on response rates and PFS has recently been demonstrated after induction and autotransplantation upfront in Multiple Myeloma (MM). We further showed that patients in ≥VGPR following the intensification procedure benefited most from consolidation. Question remains as to the benefit of consolidation for patients in PR at completion of induction - feature of partial resistance to the induction regimen.We collected data from 54 newly diagnosed MM treated with VTd-auto-VTd regimen that reached only PR at completion of the induction procedure.Overall, 37 patients (68%) improved depth of response (≥VGPR) at completion of consolidation, including 35% that reached CR and 38% solely related to consolidation. Of patients that remained on PR or improved depth of response after ASCT, 26% and 38% further responded to consolidation, respectively. With a median follow-up of 36 months, improved depth of response translated into lower relapse rate compared with patients remaining in PR, 19% vs. 36%. This difference was more striking in patients that reached CR vs. others, 8% and 38%, respectively (p=0.039). The median TTP was prolonged in patients that improved depth of response after consolidation (p=0.012), with a 3-year TTP of 87% vs. 18% otherwise. In multivariate analysis, lack of improved depth of response to consolidation independently predicted shorten median TTP [OR=4.4, 95%CI=1-21; p=0.039], with elevated LDH and beta2m, and adverse FISH.This study shows that VTd consolidation should be recommended to patients solely on PR at completion of induction with VTd, feature of lower sensitivity to VTd.
机译:在多发性骨髓瘤(MM)中预先诱导和自体移植后,近期已证实巩固对缓解率和PFS的影响。我们进一步表明,强化治疗后≥VGPR的患者受益于巩固。对于诱导完成后PR合并患者的益处-诱导方案部分抵抗的特征,仍然存在疑问。我们收集了54例新诊断的VTd-auto-VTd方案治疗的MM的数据,这些患者仅在VT完成时达到PR总体上,37例患者(68%)在巩固完成时改善了反应深度(≥VGPR),其中35%达到CR和38%仅与巩固有关。在ASCT后仍保持PR或改善反应深度的患者中,分别有26%和38%的患者对巩固治疗有进一步反应。中位随访期为36个月,与仍留在PR中的患者相比,应答深度的改善转化为较低的复发率,分别为19%和36%。达到CR的患者与其他患者相比,这一差异更为显着,分别为8%和38%(p = 0.039)。在合并后改善了反应深度的患者中,TTP的中位数延长(p = 0.012),3年期的TTP分别为87%和18%。在多变量分析中,缺乏对合并反应改善深度的预测独立预测中位TTP缩短[OR = 4.4,95%CI = 1-21; [p = 0.039],LDH和beta2m升高,且FISH不良。这项研究表明,仅在PR诱导完成VTd的情况下,仅对PR患者应建议合并VTd,因为其对VTd的敏感性较低。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号